Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 500 versus RENESE R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 500 versus RENESE R.
DIUPRES-500 vs RENESE-R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
None Documented
None Documented
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination